Clinicopathological Criteria Predictive of Recurrence Following Bacillus Calmette-Guerin Therapy Initiation in Non-Muscle-Invasive Bladder Cancer: Retrospective Cohort Study.

ABSTRACT:

Background

Bacillus Calmette-Guérin (BCG) is currently the most clinically effective intravesical treatment for non-muscle-invasive bladder cancer (NMIBC), particularly for patients with high-risk NMIBC such as those with carcinoma in situ. BCG treatments could be optimized to improve patient safety and conserve supply by predicting BCG efficacy based on tumor characteristics or clinicopathological criteria.

Objective

The aim of this study is to assess the ability of specific clinicopathological criteria to predict tumor recurrence in patients with NMIBC who received BCG therapy along various treatment timelines.

Methods

A total of 1331 patients (stage Ta, T1, or carcinoma in situ) who underwent transurethral resection of a bladder tumor between 2006 and 2017 were inc

SUBMITTER: Plasek J 

PROVIDER: S-EPMC8277393 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature